Melanoma & Skin Cancer

Axel Hauschild, MD, PhD, discusses the 5-year findings from the COMBI-AD trial.

In the phase 2 trial EMPOWER-CSCC-1, up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response for cemiplimab-rwlc in patients with advanced cutaneous squamous cell carcinoma.

The combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600–mutant melanoma.

Findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib and trametinib in patients with resected, stage III BRAF V600E/K-mutant melanoma.

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Alain Algazi, MD, discusses the SWOG S1320 trial further, the future of intermittent dosing in melanoma, and future clinical trials in the field.

Cemiplimab induced clinically meaningful and durable responses in patients with advanced basal cell carcinoma.

Nivolumab, when administered approximately 4 weeks prior to surgery in patients with Merkel cell carcinoma, was found to be tolerable and to induce pathological complete responses and radiographic tumor regressions.

Anna C. Pavlick, DO, discusses updated results from the COLUMBUS trial in metastatic melanoma.

Alain Algazi, MD, discusses the benefit of continuous dosing with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutation–positive advanced melanoma.

Ragini R. Kudchadkar, MD, discusses the biological differences between ocular melanoma and cutaneous melanoma.

Treatment with atezolizumab in combination with vemurafenib and cobimetinib was found to significantly improve progression-free survival and produce durable responses versus vemurafenib and cobimetinib alone in treatment-naïve patients with BRAF V600–mutant advanced melanoma.

Continuous dosing with dabrafenib and trametinib improved progression-free survival compared with intermittent dosing in patients with BRAF mutation–positive advanced melanoma.

Omid Hamid, MD, discusses emerging treatment approaches, the role of surgery, and ongoing research efforts in melanoma.

Investigators are testing the hypothesis that administering cetuximab with an anti–PD-L1 agent will induce immunostimulatory synergy and prolong survival in patients with cutaneous squamous cell carcinoma.

Jason J. Luke, MD, FACP, discusses the future of T-cell therapies in melanoma, emerging biomarkers, and ongoing research regarding the gut microbiome.

Ragini Kudchadkar, MD, discusses the prognosis of patients with metastatic ocular melanoma and the work being done to define novel approaches in melanoma.

Omid Hamid, MD, discusses promising triplet combination under exploration in melanoma.

STP705 met the primary efficacy end point in an ongoing phase II study of patients with cutaneous squamous cell carcinoma in situ.

The investigational RAF inhibitor lifirafenib demonstrated antitumor activity in patients with melanoma and other solid tumors.

Anna C. Pavlick, DO, discusses sequencing challenges faced in the treatment of patients with BRAF-mutant melanoma.

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses how to judiciously use steroids to manage adverse events in patients with melanoma who are receiving immunotherapy.

David Polsky, MD, PhD, discusses the use of circulating tumor DNA (ctDNA) in the COMBI-d trial on melanoma.